Why KNSA rose 20.5% on Oct 27 2026: earnings beat
KNSA+20.5%on Tue Oct 27 2026
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares was up 20.5% on the day at $87.94, ranked #5 on 19.8× its usual five-minute volume, when TapeRank recorded this spike at 09:35 ET during regular hours.
THE DAY ON THE LIST · 1 EVENT
- 09:35 ETMOVER · REGULAR
$87.94 · ▲ 20.5% ON THE DAY · 19.8× 5M RVOL · RANK #5
JUSTIFIEDCONFIDENCE5/5Kiniksa shares are up 16.5% pre-market after a substantial Q3 earnings beat and a sharp increase in full-year revenue guidance. The 51% EPS beat, 10% sales beat, and roughly 5% midpoint guidance increase provide a concrete fundamental catalyst for the move.
WHYA 16.5% move is large, but it is proportionate to the combined earnings and guidance surprise rather than unsupported by the news.ANALYZED 09:26 ET · 8 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 09:35 ET
LAST87.94DAY▲ 20.5%5 MIN▲ 4.52%5M RVOL19.8×5M $VOL$12.8MFLOAT*48.3MRANK#5SESSIONREGULARVWAP84.49HOD87.99LOD73.54OR HIGH87.99OR LOW82.26PREV CLOSE72.98PM HIGH87.11PM LOW73.54GAP▲ 16.47%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
THE SESSION
- 09:30 ETOpened at $85.00, +16.5% on the previous close of $72.98
- 09:31 ETRegular-session low, $82.26
- 13:34 ETRegular-session high, $90.80
- 15:59 ETLast trade of the regular session, $89.15, +22.2% on the previous close of $72.98
- Volume: 2.1M shares in regular hours, 61K before the open
KNSA opened at $85.00 after a strong premarket advance from the previous close, briefly dipping to $82.26 before climbing to a $90.80 high in early afternoon trading. It ended the regular session at $89.15, up 22.2% from the previous close, on 2.1M shares, with no halts. TapeRank read the move as justified by Kiniksa’s Q3 earnings beat and higher full-year sales guidance: EPS and sales exceeded estimates, while guidance rose to $1.045B-$1.050B from $980.000M-$995.000M.
WRITTEN TUE OCT 27 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 09:23 ETKiniksa Pharmaceuticals Q3 2026 Earnings Call TranscriptBenzinga
- 07:32 ET8-K — Results of Operations and Financial Condition; Financial Statements and ExhibitsSEC 8-K
- 07:31 ETKiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $980.000M-$995.000M to $1.045B-$1.050B vs $996.102M EstBenzinga
- 07:30 ETKiniksa Pharmaceuticals Q3 EPS $0.56 Beats $0.37 Estimate, Sales $285.970M Beat $260.611M EstimateBenzinga
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list